Recent Updates
Recently added Catalysts
NMRA

Neumora Therapeutics Announces IND Clearance and Initiation of Phase 1 Study of NMRA-266

Monday, November 27, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Neumora Therapeutics Announces IND Clearance and Initiation of Phase 1 Study of NMRA-266
Price reaction · baseline $11.92 (2023-11-24 close) · clean, no other NMRA news in the window
day 0 close
-0.1%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
6.5%
average across 6 past catalysts
Cash runway
~9 mo
High dilution risk
Lead asset
NMRA-335140
Phase 3 · Major Depressive Disorder

Full Press Release Details

Neumora Therapeutics Announces IND Clearance and Initiation of Phase 1 Study of NMRA-266.
ShareAdd on Google
Tags: NMRA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Nov 27, 2023

Biotech snapshot

Cash runway
$117M liquidity · $13M/mo burn
~9 mo
High dilution risk
Lead asset
NMRA-335140Phase 3
Major Depressive Disorder →

Catalyst track record

+116%
best trade around NMRA's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for NMRA.

See every catalyst's timing & PoA →